Issues related to the health insurance system are among the few important matters that seem to stay in the news. However, scrutiny has increased significantly since the audacious murder of UnitedHealthcare CEO Brian Thompson. BlueCross BlueShield (BCBS) has made some major changes since that time, but an under the radar act is now targeting a cost-saving innovator.

On December 10, 2024 — less than a week after Thompson’s unexpected death — BlueCross Blue Shield of South Carolina (BCBSSC) filed a trademark opposition against HEALTHFLEXX Inc. This company’s stated goal is to reduce healthcare costs for employers and patients by streamlining the system.

In the filing, BCBSSC claims that registration of HEALTHFLEXX’s trademark – CareCompanion – would cause confusion among consumers. They present their own trademark registrations as evidence of this, which include CompanionCare, Companion Care Solutions, Companion, Cloud Companion, Companion Data Services, and other branded properties.

While BlueCross may have a solid case that HEALTHFLEXX is engaged in trademark infringement, the company’s response couldn’t come at a worse possible time in the industry.

Setting the Stage: BlueCross Facing Backlash

The health insurance industry has long been a point of contention in America. Over the past 10 days, even those who stayed out of the conversation have been paying attention. The crime that caused this may have been the catalyst behind one of BlueCross BlueShield’s major recent decisions. Just one day after Thompson’s murder, Anthem Blue Cross rescinded a hugely unpopular policy.

This policy – which limited anesthesia coverage during surgery – was overturned on December 5. It’s worth noting that Anthem Blue Cross and BlueCross BlueShield aren’t technically the same organization. Anthem is one of the companies within the BCBS network. However, this distinction is unlikely to matter to the general public – which, by and large, despises the industry.

The decision of Anthem Blue Cross to reverse its course may have redirected some of the disdain away from the company, but their targeting of HEALTHFLEXX may disrupt some of that goodwill.

BCBS Takes on Healthcare Innovators

There are many reasons why a health insurance company like BlueCross BlueShield of South Carolina might not like HEALTHFLEXX. Put simply, the latter company is a disruptor in the industry. Its cost-reduction initiatives, including its consulting process and AI-driven health solutions, could help employers reduce healthcare costs.

In doing so, this could directly undermine a health insurance company’s ability to profit – which often relies on their ability to demand higher premiums for traditional healthcare expenses. Innovators in the field also enable employers and patients to use new technologies and devices, and this could reduce their reliance on traditional management systems controlled by insurers.

By promoting preventative care and early intervention, a company like HEALTHFLEXX could also create an environment where fewer claims are processed through traditional health insurance. Put simply, a company challenging the status quo might change everything. However, it seems that BlueCross BlueShield of South Carolina may have a legitimate grievance.

The Healthcare Trademark in Question

It’s fairly simple to see how BlueCross BlueShield of South Carolina’s trademark CompanionCare could be confused with the CareCompanion health monitoring services of HEALTHFLEXX, Inc. The U.S. Patent and Trademark Office (USPTO) would typically not allow such a likelihood of confusion to exist.

Put simply, both companies’ trademarks are within the healthcare industry and focus on patient data, care, and other resources. According to the filing submitted by BCBSSC, January 19, 2025, is the deadline for HEALTHFLEXX to respond. The healthcare innovator seems to have removed most of their CareCompanion web pages, so this fight might be a foregone conclusion.

Still, with the health insurance industry facing heightened scrutiny – targeting a cost-reduction innovator, even for legitimate reasons, could be a PR issue.